Short answer
CapsoVision, Inc (CV) filed its Q2 2026 10-Q quarterly report on Aug 13, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $4M (down 40.3% year over year) with net income of −$7M.
Q2 2026 key financials · XBRL
- Revenue
- $4M
- −40.3% YoY · +30.5% QoQ
- Net income
- −$7M
- +25.2% YoY · −6.4% QoQ
- Operating margin
- -208.1%
- Gross margin
- 51.4%
- EPS (diluted)
- −$0.15
- +96.7% YoY · +0.0% QoQ
Source: XBRL data from the CapsoVision, Inc (CV) Q2 2026 10-Q on SEC EDGAR. USD.
CapsoVision, Inc Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $3.643M, up 10% YoY from $3.315M, driven by 13% higher CapsoCam Plus unit sales
- Gross margin 51% vs 55% YoY; operating loss $7.580M vs $4.651M
- R&D expenses $5.309M, up 57% YoY, primarily clinical trials and Canon CMOS sensor development
- Six-month customs and tariffs added $0.1M; management cited competitive pricing pressure and tariff headwinds
- CapsoCam Colon pivotal study enrollment completed with 801 patients; 510(k) submission expected Q4 2026
Risk Factors
- New pancreatic-cancer study triggered by January 2026 FDA rejection of Breakthrough Device Designation application
- Going-concern risk intensified with $9.1 million cash and additional financing likely before year-end 2026
- FDA clearance risk for second-generation CapsoCam Colon tied to planned fourth-quarter 2026 510(k) submission
- Market concentration in CapsoCam Plus small-bowel sales, with CapsoCam Colon revenue not expected until FDA clearance
- Taiwan and Japan supply exposure, including single-source suppliers and heightened Taiwan Strait tensions
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CapsoVision, Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.